Evidence map›Paper›PMID 33923830›Full record

ArticleMedicina (Kaunas, Lithuania)2021

The Role of Prevention in Reducing the Economic Impact of ME/CFS in Europe: A Report from the Socioeconomics Working Group of the European Network on ME/CFS (EUROMENE).

Derek F H Pheby, Diana Araja, Uldis Berkis, Elenka Brenna, John Cullinan, Jean-Dominique de Korwin, Lara Gitto, Dyfrig A Hughes, Rachael M Hunter, Dominic Trepel and 1 more

Abstract read
In one paragraph

Article in Medicina (Kaunas, Lithuania), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Turning a Corner in ME/CFS Research.Medicina (Kaunas, Lithuania) · 2021
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Derek F H PhebySociety and Health, Buckinghamshire New University, High Wycombe HP11 2JZ, UK.ORCID 0000-0003-1726-0717
Diana ArajaDepartment of Dosage Form Technology, Faculty of Pharmacy, Riga Stradins University, Dzirciema Street 16, LV-1007 Riga, Latvia.ORCID 0000-0002-4558-0980
Uldis BerkisInstitute of Microbiology and Virology, Riga Stradins University, Dzirciema Street 16, LV-1007 Riga, Latvia.
Elenka BrennaDepartment of Economics and Finance, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli 1, 20123 Milan, Italy.ORCID 0000-0003-3332-9614
John CullinanSchool of Business & Economics, National University of Ireland Galway, University Road, H91 TK33 Galway, Ireland.ORCID 0000-0003-3509-0635
Jean-Dominique de KorwinInternal Medicine Department, University of Lorraine, 34, Cours Léopold CS 25233, F-54052 Nancy, France.ORCID 0000-0003-2998-2207
Lara GittoDepartment of Economics, University of Messina, Piazza Pugliatti 1, 98122 Messina, Italy.ORCID 0000-0002-0510-9238
Dyfrig A HughesCentre for Health Economics & Medicines Evaluation, Bangor University, Bangor LL57 2PZ, UK.ORCID 0000-0001-8247-7459
Rachael M HunterDepartment of Primary Care and Population Health, Royal Free Medical School, University College London, London NW3 2PF, UK.ORCID 0000-0002-7447-8934
Dominic TrepelGlobal Brain Health Institute, School of Medicine, Trinity College Dublin, College Green, D02 PN40 Dublin, Ireland.ORCID 0000-0002-1421-2966
Xia Wang-SteverdingWarwick Medical School, University of Warwick, Coventry CV4 7AL, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This report addresses the extent to which there may be scope for preventive programmes for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), and, if so, what economic benefits may accrue from the implementation of such programmes. We consider the economic case for prevention programmes, whether there is scope for preventive programmes for ME/CFS, and what are the health and economic benefits to be derived from the implementation of such programmes. We conclude that there is little scope for primary prevention programmes, given that ME/CFS is attributable to a combination of host and environmental risk factors, with host factors appearing to be most prominent, and that there are few identified modifiable risk factors that could be the focus of such programmes. The exception is in the use of agricultural chemicals, particularly organophosphates, where there is scope for intervention, and where Europe-wide programmes of health education to encourage safe use would be beneficial. There is a need for more research on risk factors for ME/CFS to establish a basis for the development of primary prevention programmes, particularly in respect of occupational risk factors. Secondary prevention offers the greatest scope for intervention, to minimise diagnostic delays associated with prolonged illness, increased severity, and increased costs.

Indexed as

Fatigue Syndrome, ChronicEuropeHumansSocioeconomic Factorschronic fatigue syndromeeconomic impactME/CFSmyalgic encephalomyelitisprevention

Identifiers

PMID33923830
PMCPMC8073750

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.